A threshold mechanism mediates p53 cell fate decision between growth arrest and apoptosis

The p53 tumor suppressor responds to certain cellular stresses by inducing transcriptional programs that can lead to growth arrest or apoptosis. However, the molecular mechanisms responsible for choosing between these two cell fates are not well understood. Previous studies have suggested that p53 selectively activates proarrest target genes, due to the higher affinity of p53 for their promoters compared with proapoptotic genes. Here we show using microarray and chromatin immunoprecipitation that p53 binds to and transcriptionally activates both its proarrest and proapoptotic target genes proportionally to induced p53 expression levels. Further, we provide evidence that to trigger apoptosis, cells must overcome an apoptotic threshold, whose height is determined by expression levels of p53 and its targets, the duration of their expression and the cellular context. We demonstrate in multiple cells lines that below this threshold, expression levels of p53 and its targets were sufficient to induce arrest but not apoptosis. Above this threshold, p53 and its targets triggered extensive apoptosis. Moreover, lowering this threshold with inhibitors of antiapoptotic Bcl-2 family proteins sensitized cells to p53-induced apoptosis. These findings argue that agents that lower the apoptotic threshold should increase the efficacy of p53-mediated cancer therapy.

[1]  Lewis A. Chodosh,et al.  Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis , 2007, Nature Cell Biology.

[2]  B. Kennedy,et al.  NPAT links cyclin E-Cdk2 to the regulation of replication-dependent histone gene transcription. , 2000, Genes & development.

[3]  Fergus J Couch,et al.  p53 Mediates Repression of the BRCA2 Promoter and Down-regulation of BRCA2 mRNA and Protein Levels in Response to DNA Damage* , 2003, The Journal of Biological Chemistry.

[4]  Andrew W. Millar,et al.  Rethinking clinical trials for cytostatic drugs , 2003, Nature Reviews Cancer.

[5]  Judith Roth,et al.  A polymorphic microsatellite that mediates induction of PIG3 by p53 , 2002, Nature Genetics.

[6]  G. Lozano,et al.  Regulation of tissue‐ and stimulus‐specific cell fate decisions by p53 in vivo , 2011, The Journal of pathology.

[7]  M. Stampfer,et al.  Induction of transformation and continuous cell lines from normal human mammary epithelial cells after exposure to benzo[a]pyrene. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Alan R. Fersht,et al.  Awakening guardian angels: drugging the p53 pathway , 2009, Nature Reviews Cancer.

[9]  O. Myklebost,et al.  Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[10]  J. Pietenpol,et al.  Kinetics of p53 Binding to Promoter Sites In Vivo , 2001, Molecular and Cellular Biology.

[11]  A Sewing,et al.  High-intensity Raf signal causes cell cycle arrest mediated by p21Cip1 , 1997, Molecular and cellular biology.

[12]  P. Sorger,et al.  Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis , 2009, Nature.

[13]  Eduardo Sontag,et al.  Transcriptional control of human p53-regulated genes , 2008, Nature Reviews Molecular Cell Biology.

[14]  P. Ouillette,et al.  Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia. , 2010, Blood.

[15]  Xin Lu,et al.  Live or let die: the cell's response to p53 , 2002, Nature Reviews Cancer.

[16]  R. Iggo,et al.  Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[17]  M. Oren,et al.  Decision making by p53: life, death and cancer , 2003, Cell Death and Differentiation.

[18]  R. Eils,et al.  Mathematical modeling reveals threshold mechanism in CD95-induced apoptosis , 2004, The Journal of cell biology.

[19]  T. Lawrence,et al.  Global Genechip Profiling to Identify Genes Responsive to p53-Induced Growth Arrest and Apoptosis in Human Lung Carcinoma Cells , 2003, Cancer biology & therapy.

[20]  C. Tse,et al.  ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. , 2008, Cancer research.

[21]  Gema Moreno-Bueno,et al.  Transcriptional profiling of MCF7 breast cancer cells in response to 5‐Fluorouracil: Relationship with cell cycle changes and apoptosis, and identification of novel targets of p53 , 2006, International journal of cancer.

[22]  S. Lowe,et al.  The p53–Bcl-2 connection , 2006, Cell Death and Differentiation.

[23]  C. Prives,et al.  Blinded by the Light: The Growing Complexity of p53 , 2009, Cell.

[24]  J. Wiels,et al.  Treatment with a BH3 mimetic overcomes the resistance of latency III EBV (+) cells to p53-mediated apoptosis , 2011, Cell Death and Disease.

[25]  H. Abaan,et al.  Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. , 2006, Journal of medicinal chemistry.

[26]  T. Hunter,et al.  Nuclear Translocation of Caspase-3 Is Dependent on Its Proteolytic Activation and Recognition of a Substrate-like Protein(s)* , 2005, Journal of Biological Chemistry.

[27]  G. Evan,et al.  Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. , 2006, Cancer cell.

[28]  Peter K. Sorger,et al.  Measuring and Modeling Apoptosis in Single Cells , 2011, Cell.

[29]  Luquan Wang,et al.  Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progression , 2003, Oncogene.

[30]  Karen H. Vousden,et al.  p53 in health and disease , 2007, Nature Reviews Molecular Cell Biology.

[31]  David P. Lane,et al.  Translating p53 into the clinic , 2010, Nature Reviews Clinical Oncology.

[32]  S. Lowe,et al.  Intrinsic tumour suppression , 2004, Nature.

[33]  Augusto Silva,et al.  Double Bolt Regulation of Rad51 by p53: A Role for Transcriptional Repression , 2006, Cell cycle.

[34]  L. Vassilev,et al.  p21 does not protect cancer cells from apoptosis induced by nongenotoxic p53 activation , 2011, Oncogene.

[35]  Yves Pommier,et al.  γH2AX and cancer , 2008, Nature Reviews Cancer.

[36]  D. Notterman,et al.  Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. , 2000, Genes & development.

[37]  E. Appella,et al.  Growth suppression induced by wild-type p53 protein is accompanied by selective down-regulation of proliferating-cell nuclear antigen expression. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Qiang Yu,et al.  p53-regulated Transcriptional Program Associated with Genotoxic Stress-induced Apoptosis* , 2004, Journal of Biological Chemistry.

[39]  D. Ginsberg,et al.  p53 and E2f: partners in life and death , 2009, Nature Reviews Cancer.

[40]  Sam W. Lee,et al.  Influence of Induced Reactive Oxygen Species in p53-Mediated Cell Fate Decisions , 2003, Molecular and Cellular Biology.

[41]  K. Vousden,et al.  Coping with stress: multiple ways to activate p53 , 2007, Oncogene.

[42]  O. Pereira-smith,et al.  p53 is preferentially recruited to the promoters of growth arrest genes p21 and GADD45 during replicative senescence of normal human fibroblasts. , 2006, Cancer research.

[43]  S. Aaronson,et al.  Wnt pathway aberrations including autocrine Wnt activation occur at high frequency in human non-small-cell lung carcinoma , 2009, Oncogene.

[44]  X. Chen,et al.  p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. , 1996, Genes & development.

[45]  G. Evan,et al.  Distinct thresholds govern Myc's biological output in vivo. , 2008, Cancer cell.

[46]  F. Murray-Zmijewski,et al.  A complex barcode underlies the heterogeneous response of p53 to stress , 2008, Nature Reviews Molecular Cell Biology.

[47]  T. Sasagawa,et al.  Characterization of adriamycin-induced G2 arrest and its abrogation by caffeine in FL-amnion cells with or without p53. , 2001, Experimental cell research.

[48]  G. Wahl,et al.  Regulating the p53 pathway: in vitro hypotheses, in vivo veritas , 2006, Nature Reviews Cancer.